Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04995094
Title Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors HiberCell, Inc.
Indications

skin melanoma

melanoma

Therapies

Pembrolizumab

Pembrolizumab + PGG beta-glucan

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.